Bayer stock: Bayer sets November 3 results date. Bayer stock gains 2.32 percent

Published on 10/21/2026 at 15:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer's first-half sales rose 3.00 percent to EUR 24.30 billion. Bayer stock costs EUR 44.49 on October 21, 2026, up 2.32 percent versus the Xetra close.

Reporting date and stock position

Bayer scheduled its third-quarter results for November 3, 2026.
First-half sales rose 3.00 percent to EUR 24.30 billion.
Bayer stock costs EUR 44.49 at Lang & Schwarz on October 21, 2026 at 3:34 p.m. CEST, 2.32 percent above the Xetra close of October 20, 2026.
Bayer's market capitalization is EUR 43.5 billion and its 52-week range is EUR 25.78 to EUR 53.92.

Flaches Vintage-Grafikposter im Bauhaus-Stil: LEVERKUSEN als fette Überschrift, SEIT 1863 als Subline, zentrales hexagonales Molekülmotiv in Rot-Schwarz-Gold, Industrie- und Brückensilhouetten — Bauhaus-Retro-Poster mit Text LEVERKUSEN / SEIT 1863, geometrischem Benzolring-Motiv und Industrie-Silhouetten, Illustration mit AI erstellt.

Bayer has scheduled publication of its third-quarter results for November 3, 2026, according to Bayer. The date puts the next company update within two weeks, while Bayer stock was trading at EUR 44.49 at Lang & Schwarz on October 21, 2026 at 3:34 p.m. CEST, up 2.32 percent versus the Xetra close of October 20, 2026 at EUR 43.48.

First-half sales set the baseline

Bayer reported first-half sales of EUR 24.30 billion, an increase of 3.00 percent, in its August 4, 2026 investor update. The company said group sales in the second quarter increased 2.20 percent to EUR 10.872 billion, while EBITDA before special items rose 1.90 percent to EUR 2.144 billion.

The first-half figures give investors a measurable starting point for the November report. Bayer's three operating areas are Pharmaceuticals, Consumer Health and Crop Science, with the latter contributing to the reported earnings improvement during the second quarter.

Stock remains below its yearly high

The EUR 44.49 quotation stands 17.49 percent below Bayer's 52-week high of EUR 53.92 and 72.57 percent above its 52-week low of EUR 25.78. The market capitalization is EUR 43.5 billion, while the price-to-earnings ratio is negative 25.22.

Bayer's current quotation is above the October 20 Xetra close by EUR 1.01. The company stock therefore enters the final part of the October session above its previous Xetra reference, with the November reporting date as the next scheduled corporate event.

Valuation and reporting date

The November 3 release is scheduled for 7:30 a.m. CET, followed by the investor call at 2:00 p.m. CET, according to Bayer. The company has identified the release as its third-quarter results publication, making the reporting date more concrete than a general calendar entry.

Bayer's first-half sales growth of 3.00 percent compares with the 2.20 percent second-quarter increase reported for the same period. That sequence gives the upcoming figures two reference points: the full six months and the latest quarter.

Comparison with peers

Bayer: up 2.32 percent versus the October 20 Xetra close, P/E negative 25.22, market capitalization EUR 43.5 billion.

BASF: up 0.70 percent on Xetra at EUR 53.00 on October 21, 2026, P/E 7.97, market capitalization EUR 45.7 billion.

Merck KGaA: down 1.02 percent on Xetra at EUR 144.90 on October 21, 2026, P/E 26.60, market capitalization EUR 63.0 billion.

November date sets the next test

The scheduled release will provide the next dated comparison for Bayer's sales and earnings after the first-half increase. Until then, the stock's EUR 44.49 quotation remains below its EUR 53.92 yearly high and above the October 20 Xetra close.

The further course of trading is shown by the continuously updated real-time quote of Bayer stock.